Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 22nd May 2013 09:37

Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation.Amara Mining: Westhouse Securities cuts target price from 110p to 90p retaining a buy recommendation.Amlin: Westhouse Securities moves target price from 455p to 470p and upgrades to add.ARM Holdings: Berenberg increases target price from 1150p to 1350p and maintains a buy recommendation.Beazley: Westhouse Securities shifts target price from 235p to 245p, while downgrading to neutral.Britvic: Investec places both its target price (prev.: 447p) and its buy recommendation under review.Burberry: JP Morgan increases target price from 1320p to 1400p and keeps a neutral rating. Deutsche Bank raises target price from 1400p to 1530p, while its hold recommendation remains unchanged. Credit Suisse ups target price from 1550p to 1600p and maintains an outperform rating.Capita Group: Investec ups target price from 865p to 1000p upgrading from sell to hold. HSBC Holdings increases target price from 775p to 1050p upgrading to neutral.Carnival: Morgan Stanley reduces target price from 2400p to 2200p, while reiterating an equal-weight rating. Deutsche Bank cuts target price from 2780p to 2640p staying with its buy recommendation. Exane takes target price from 2400p to 2200p and retains a neutral rating. HSBC Holdings reduces target price from 2900p to 2500p and downgrades to neutral.Catlin Group: Westhouse Securities takes target price from 530p to 590p upgrading to add.Darty: Citi shifts target price from 39p to 47p, but still recommends selling. Exane moves target price from 50p to 65p and maintains a neutral rating. Societe Generale takes target price from 51p to 68p, while downgrading to hold.Faroe Petroleum: Jefferies lowers target price from 210p to 200p, while keeping its buy recommendation.First Group: Morgan Stanley cuts target price from 195p to 176p, while upgrading to equal-weight.GlaxoSmithKline: Exane raises target price from 1400p to 1500p, but keeps its underperform rating.Great Portland Estates: Investec increases target price from 515p to 630p, while reiterating an add rating.Griffin Mining: Cantor Fitzgerald ups target price from 40p to 70p and upgrades to buy.Hikma Pharmaceuticals: Credit Suisse takes target price from 820p to 1050p, while its outperform rating is kept.Hiscox: Westhouse Securities shifts target price from 530p to 540p and keeps a neutral rating.Hogg Robinson Group: Investec lowers target price from 100p to 95p, while maintaining its buy recommendation. Canaccord Genuity shifts target price from 90p to 85p and retains a buy recommendation.Homeserve: Jefferies ups target price from 210p to 240p keeping a hold recommendation.HSBC Holdings: Bank of America ups target price from 755p to 785p and reiterates a neutral rating.Imagination Technologies Group: Berenberg reduces target price from 360p to 250p and leaves its sell recommendation unchanged.Informa: Westhouse Securities downgrades from add to neutral with a target price of 525p.Innovation Group: Investec moves target price from 30p to 33p maintaining a buy recommendation. Panmure Gordon shifts target price from 38p to 39p and keeps a buy recommendation.Invensys: Exane raises target price from 350p to 380p reiterating a neutral rating.Kazakhmys: UBS reduces target price from 465p to 385p and downgrades from buy to neutral.Magnolia Petroleum: Northland Capital initiates with a target price of 4.60p and a buy recommendation.Man Group: Citi moves target price from 110p to 130p and retains a neutral rating.Marks & Spencer: Nomura increases target price from 500p to 540p maintaining a buy recommendation. Citi ups target price from 440p to 470p and stays with its neutral rating. Deutsche Bank moves target price from 450p to 465p and leaves its hold recommendation unaltered. Exane raises target price from 310p to 390p keeping an underperform rating. Societe Generale ups target price from 472p to 581p and retains a buy recommendation. HSBC Holdings takes target price from 390p to 490p and maintains a neutral rating.MITIE: Jefferies cuts target price from 300p to 285p and maintains a hold recommendation.NetDimensions: Panmure Gordon ups target price from 118p to 124p reiterating its buy recommendation.Novae Group: Westhouse Securities raises target price from 450p to 500p and retains a neutral rating.Optimal Payments: Canaccord Genuity takes target price from 200p to 220p and retains a buy recommendation.Optos: N+1 Singer reduces target price from 150p to 135p, while upgrading to hold.Paragon Group: JP Morgan moves target price from 300p to 361p maintaining an overweight rating.Petropavlovsk: Westhouse Securities lowers target price from 285p to 275p keeping its buy recommendation.PZ Cussons: Panmure Gordon increases target price from 380p to 400p and retains a hold recommendation.RPS Group: Jefferies lowers target price from 285p to 275p, while leaving its buy recommendation unchanged.Shaftesbury: Investec takes target price from 550p to 690p and retains a hold recommendation.UK Mail Group: Investec raises target price from 465p to 600p and stays with its buy recommendation.Vectura: JP Morgan shifts target price from 133p to 148p and stays with its overweight rating.
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.